Industry & Policy News

[Science Insider] Although below the rate of biomedical inflation, it is far more generous than a corresponding House of Representatives bill that would slash NIH’s budget by 6%.

[Citius Pharmaceuticals, Inc.] Citius Pharmaceuticals, Inc. announced that the US FDA has issued a Complete Response Letter regarding the Company's Biologics License Application seeking approval for denileukin diftitox.

[Invectys, Inc.] Invectys, Inc. announced the US FDA has granted Fast Track designation to its revolutionary product, IVS-3001, a CAR-T cell immunotherapy that targets the rarely exploited immune checkpoint and tumor-specific antigen known as HLA-G.

[ISS National Lab] Researchers at Emory University will leverage the International Space Station National Laboratory to continue examining how microgravity affects the growth and function of cardiomyocytes as they mature into tissue-like structures.

[SCIENCEINSIDER] Mexico’s controversial new science law, which seeks to reshape government research funding and governance, is facing a flurry of legal challenges.

[Telavant] Telavant announced the initiation of the TAHOE study, a Phase II clinical trial of RVT-3101 for the treatment of moderate to severely active Crohn's disease, with the first patient dosed.